Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Eyes on! TB on hourly! Plus data release coming could help bring volume to help push this bullish formation!

$Olema Pharmaceuticals (OLMA.US)$ Olema Oncology to Present New Data Combining Palazestrant With Ribociclib at the San Antonio Breast Cancer Symposium
Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024
Poster Details
Title:A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-), advanced or metastatic breast cancerPoster ID:P2-09-16Session:Poster Session 2Date/Time:Wednesday, December 11, 2024, from 5:30 to 7:00 p.m. CT
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
13
Translate
Report
2346 Views
Comment
Sign in to post a comment

View more comments...

3651Followers
23Following
54KVisitors
Follow